figshare
Browse
12943_2017_662_MOESM2_ESM.pdf (474.6 kB)

Additional file 2: Figure S2. of Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

Download (474.6 kB)
journal contribution
posted on 2017-05-30, 05:00 authored by Francesca Ricci, Federica Guffanti, Giovanna Damia, Massimo Broggini
Body weight of animals treated with vehicle (CTR,-♦-), with Bevacizumab and MEK162 (BEV/MEK,-■-), paclitaxel and MEK162 (PTX/MEK,-▲-), paclitaxel and bevacizumab (PTX/BEV, -●-), or paclitaxel and bevacizumab and MEK162 (PTX/BEV/MEK,-x-). Data are expressed as mean±SD, each group consisted of 8-10 animals. A) MNHOC124 PDX model, B) MNHOC218 PDX model and C) MNHOC239 PDX model. (PDF 474 kb)

Funding

Associazione Italiana per la Ricerca sul Cancro

History

Usage metrics

    Molecular Cancer

    Categories

    Keywords

    Ovarian cancerSecond linePatients derived xenograftsCisplatinDrug resistanceCombination chemotherapy

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC